Nuvation Bio (NUVB) Other Operating Expenses (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Other Operating Expenses of $6.0 million for Q1 2026, up 186.1% year-over-year from $2.1 million in Q1 2025, and up 199800.0% quarter-over-quarter from -$3000.0 in Q4 2025.
Powered by 
Analysis
Nuvation Bio (NUVB) Other Operating Expenses (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Other Operating Expenses for 3 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 186.1% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (up 184.53% YoY), while the FY2025 annual figure was -$33000.0, changed N/A from the prior year.
- Other Operating Expenses rose to $6.0 million in Q1 2026 per NUVB's latest filing, from -$3000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $6.0 million in Q1 2026 and bottomed at -$34000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Nuvation Bio | 2.38 Bn | 2.38 Bn | 30.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Mar 31, 2026 | 5.99 Mn |
| Dec 31, 2025 | -3,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Jun 30, 2025 | -34,000.00 |
| Mar 31, 2025 | 2.09 Mn |
| Dec 31, 2020 | 1.37 Mn |